Extrawell Pharmaceutical Holdings Dividend

Dividend criteria checks 0/6

Extrawell Pharmaceutical Holdings does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	3.4%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-HK$0.065
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Mar 18

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

Dec 01

We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Aug 04

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Mar 15

Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Aug 20

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if 858's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 858's dividend payments have been increasing.

Dividend Yield vs Market

Extrawell Pharmaceutical Holdings Dividend Yield vs Market

How does 858 dividend yield compare to the market?
Segment	Dividend Yield
Company (858)	n/a
Market Bottom 25% (HK)	3.2%
Market Top 25% (HK)	7.8%
Industry Average (Pharmaceuticals)	3.4%
Analyst forecast in 3 Years (858)	n/a

Notable Dividend: Unable to evaluate 858's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 858's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate 858's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 858 has not reported any payouts.

Extrawell Pharmaceutical Holdings Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

New major risk - Share price stability

New major risk - Market cap size

First half 2024 earnings released: HK$0.099 loss per share (vs HK$0.019 profit in 1H 2023)

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

New major risk - Revenue and earnings growth

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Nov 29, 2023

New minor risk - Share price stability

Full year 2023 earnings released: EPS: HK$0.054 (vs HK$0.055 in FY 2022)

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 25, 2023

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: HK$0.054 (vs HK$0.055 in FY 2022)

New minor risk - Financial data availability

Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023

Extrawell Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Jun 29, 2023

Extrawell Pharmaceutical Holdings Limited Announces Demise of Mr. Xue Jing Lun, Independent Non-Executive Director, and A Member of Each of the Audit Committee, Remuneration Committee and Nomination Committee

First half 2023 earnings released: EPS: HK$0.019 (vs HK$0.037 in 1H 2022)

Extrawell Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 September 2022

Less than half of directors are independent

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Nov 29, 2022

Extrawell Pharmaceutical Holdings Limited Announces Management Changes

We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Full year 2022 earnings released: EPS: HK$0.055 (vs HK$0.051 loss in FY 2021)

Extrawell Pharmaceutical Holdings Limited, Annual General Meeting, Aug 30, 2022

Full year 2022 earnings released

Extrawell Pharmaceutical Holdings Limited Provides Earnings Guidance for the Year Ended March 31, 2022

Extrawell Pharmaceutical Holdings Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Full year 2021 earnings released: HK$0.051 loss per share (vs HK$0.035 profit in FY 2020)

Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended March 31, 2021

First half 2021 earnings released: EPS HK$0.031

First half 2021 earnings released: EPS HK$0.031

Extrawell Pharmaceutical Holdings Limited to Report First Half, 2021 Results on Nov 27, 2020

Mao Yumin completed the acquisition of 19.14% stake in Extrawell Pharmaceutical Holdings Limited (SEHK:858) from Innovative Pharmaceutical Biotech Limited (SEHK:399).

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies